113,915 results match your criteria non-hodgkin lymphoma


Correlation between tobacco control policies and mortality of haematological cancers across Europe: An ecological study.

Tob Prev Cessat 2021 30;7:31. Epub 2021 Apr 30.

Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, United States.

Introduction: To determine the correlation between tobacco control policies and mortality of haematological malignancies: leukemia, lymphoma and multiple myeloma (MM).

Methods: Ecological study with the countries as the unit of analysis. Tobacco Control Scale (TCS) scores from 2010, 2013 and 2016 were used as measures for the level of tobacco control policy implementation in 27 European countries. Read More

View Article and Full-Text PDF

Diagnostic Performance of Pretreatment 18F-Fluorodeoxyglucose Positron Emission Tomography With or Without Computed Tomography in Patients With Primary Central Nervous System Lymphoma: Updated Systematic Review and Diagnostic Test Accuracy Meta-analyses.

Clin Lymphoma Myeloma Leuk 2021 Apr 3. Epub 2021 Apr 3.

Department of Nuclear Medicine & Molecular Imaging, ACTREC/TMH, Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Mumbai, India.

This review aimed to assess diagnostic performance of 18F-flouro-deoxy-glucose positron emission tomography (FDG-PET) with or without computed tomography (CT) scan in primary central nervous system lymphoma (PCNSL). Eligible studies reporting diagnostic accuracy of pretreatment FDG-PET(CT) scan in immunocompetent adults with PCNSL were identified through systematic literature search. Data on diagnostic performance from individual studies was summarized in a 2 × 2 table classifying patients as true positives, true negatives, false positives, and false negatives using histopathologic diagnosis as reference standard. Read More

View Article and Full-Text PDF

Integration of Metabolomics and Gene Expression Profiling Elucidates IL4I1 as Modulator of Ibrutinib Resistance in ABC-Diffuse Large B Cell Lymphoma.

Cancers (Basel) 2021 Apr 29;13(9). Epub 2021 Apr 29.

Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA.

Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma (NHL). B-cell NHLs rely on Bruton's tyrosine kinase (BTK) mediated B-cell receptor signaling for survival and disease progression. However, they are often resistant to BTK inhibitors or soon acquire resistance after drug exposure resulting in the drug-tolerant form. Read More

View Article and Full-Text PDF

Bispecific Antibodies: A Review of Development, Clinical Efficacy and Toxicity in B-Cell Lymphomas.

J Pers Med 2021 Apr 29;11(5). Epub 2021 Apr 29.

Monash Haematology, Monash Health, Clayton, VIC 3168, Australia.

The treatment landscape of B-cell lymphomas is evolving with the advent of novel agents including immune and cellular therapies. Bispecific antibodies (bsAbs) are molecules that recognise two different antigens and are used to engage effector cells, such as T-cells, to kill malignant B-cells. Several bispecific antibodies have entered early phase clinical development since the approval of the CD19/CD3 bispecific antibody, blinatumomab, for relapsed/refractory acute lymphoblastic leukaemia. Read More

View Article and Full-Text PDF

Genetic Events Inhibiting Apoptosis in Diffuse Large B Cell Lymphoma.

Cancers (Basel) 2021 Apr 30;13(9). Epub 2021 Apr 30.

Department of Medicine, McGill University, Montreal, QC H4A 3J1, Canada.

Diffuse large B cell lymphoma (DLBCL) is curable with chemoimmunotherapy in ~65% of patients. One of the hallmarks of the pathogenesis and resistance to therapy in DLBCL is inhibition of apoptosis, which allows malignant cells to survive and acquire further alterations. Inhibition of apoptosis can be the result of genetic events inhibiting the intrinsic or extrinsic apoptotic pathways, as well as their modulators, such as the inhibitor of apoptosis proteins, P53, and components of the NF-kB pathway. Read More

View Article and Full-Text PDF

Article Topic/Title: Primary cutaneous T-cell lymphomas other than Mycosis Fungoides and Sezary Syndrome. Part II: Prognosis and Management.

J Am Acad Dermatol 2021 May 1. Epub 2021 May 1.

Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address:

Primary cutaneous T-cell lymphomas (CTCLs) other than Mycosis Fungoides (MF) and Sézary syndrome (SS) encompass a heterogenous group of non-Hodgkin lymphomas with variable clinical course, prognoses, and management. With morphologic and histologic overlap among the CTCL subtypes and other T-cell lymphomas with cutaneous manifestations, thorough evaluation with clinicopathologic correlation and exclusion of systemic involvement are essential prior to initiating therapy. Staging and treatment recommendations vary depending on the subtype, clinical behavior, and treatment response. Read More

View Article and Full-Text PDF

Trends in childhood cancer incidence in sub-Saharan Africa: Results from 25 years of cancer registration in Harare (Zimbabwe) and Kyadondo (Uganda).

Int J Cancer 2021 May 4. Epub 2021 May 4.

Institute of Medical Epidemiology, Biostatistics and Informatics, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.

We examined trends in childhood cancer incidence in sub-Saharan Africa using data from two population-based cancer registries in Harare (Zimbabwe) and Kyadondo (Uganda) with cases classified according to the International Classification of Childhood Cancer and explored reasons for observed variations and changes. Over the whole 25-year period (1991-2015) studied, there were only small, and non-significant overall trends in incidence. Nevertheless, within the period, peaks in incidence occurred from 1996-2001 in Harare (Zimbabwe) and from 2003-2006 in Kyadondo (Uganda). Read More

View Article and Full-Text PDF

Mucosa-associated lymphoid tissue lymphoma of the parotid gland - a case report.

Med Ultrason 2021 Apr 28. Epub 2021 Apr 28.

"Iuliu Hațieganu" University of Medicine and Pharmacy, Department of Maxillofacial Surgery and Implantology, 33 Moților Street, 400001, Cluj-Napoca, Romania.

Mucosa-associated lymphoid tissue (MALT) lymphoma of the parotid gland is a rare entity among head and neck tumours. We report a case of a patient with a medical history of diffuse large B-cell Non-Hodgkin Lymphoma with complete remission following chemotherapy, who presented seven years afterwards with a progressive painless hard swelling of the right parotidgland. Ultrasonography followed by contrast-enhanced MRI features was consistent with a malignant tumour. Read More

View Article and Full-Text PDF

Successful treatment of EBV-associated Primary CNS Lymphoma due to PTLD, with Ibrutinib and 3 Party EBV-specific T cells.

Am J Transplant 2021 May 4. Epub 2021 May 4.

Mater Research Institute UQ, Brisbane, Australia.

Primary central nervous system lymphoma (PCNSL) occurring following organ transplantation (post-transplantation lymphoproliferative disorder 'PTLD') is a highly aggressive non-Hodgkin lymphoma. It is typically treated with high-dose methotrexate-based regimens. Outcomes are dismal and clinical trials are lacking. Read More

View Article and Full-Text PDF

Primary cutaneous T-cell lymphomas other than Mycosis Fungoides and Sezary Syndrome - Part I: Clinical and histologic features and diagnosis.

J Am Acad Dermatol 2021 Apr 30. Epub 2021 Apr 30.

Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address:

Primary cutaneous T-cell lymphomas (CTCLs) are defined as lymphomas with a T-cell phenotype that present in the skin without evidence of systemic or extracutaneous disease at initial presentation. CTCLs other than Mycosis Fungoides (MF) and Sézary syndrome (SS) account for approximately one-third of CTCLs and encompass a heterogenous group of non-Hodgkin lymphomas ranging from indolent lymphoproliferative disorders to aggressive malignancies with a poor prognosis. The spectrum of CTCLs continues to broaden as new provisional entities are classified. Read More

View Article and Full-Text PDF

Chemotherapy for non-Hodgkin lymphoma in the hemodialysis patient: a comprehensive review.

Cancer Sci 2021 May 3. Epub 2021 May 3.

Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan.

Chemotherapy for non-Hodgkin lymphoma (NHL) in the hemodialysis (HD) patient is a challenging situation. Because many drugs are predominantly eliminated by the kidneys, chemotherapy in the HD patient requires special considerations concerning dose adjustments to avoid overdose and toxicities. Conversely, some drugs are removed by HD and may expose the patient to undertreatment, and therefore timing of drug administration in relation to HD sessions must be carefully planned. Read More

View Article and Full-Text PDF

Lymphoma Masquerading as an Ear Mass.

Cureus 2021 Mar 29;13(3):e14180. Epub 2021 Mar 29.

Internal Medicine, University of Texas Health Science Center at Houston, Houston, USA.

Due to the infrequently reported location, malignancies of the ear are usually misdiagnosed at the time of first presentation. To the best of our knowledge, there have been no reports in literature regarding diffuse large B-cell lymphoma (DLBCL) presenting as an ear mass, as was seen in our patient. We describe a case of a 38-year-old gentleman who presented with four months of worsening dyspnea on exertion and nonproductive cough. Read More

View Article and Full-Text PDF

Electrolyte disorders secondary to venetoclax.

Clin Kidney J 2021 Apr 15;14(4):1272-1274. Epub 2020 Jun 15.

Department of Internal Medicine, Erasmus Medical Center, University Medical Center Rotterdam, Rotterdam, The Netherlands.

Emerging cancer drugs introduce new forms of nephrotoxicity that may also present as electrolyte disorders. Here, we report a patient with non-Hodgkin lymphoma who developed severe hypokalaemia with concurrent hypophosphataemia, hypocalcaemia and hypomagnesaemia secondary to venetoclax. Although electrolyte disorders have been reported during treatment with venetoclax, these were ascribed to tumour lysis prophylaxis. Read More

View Article and Full-Text PDF

Binucleate Cells in Cytosmears: What do They Signify?

J Cytol 2021 Jan-Mar;38(1):38-43. Epub 2021 Feb 16.

Department of Pathology, Pondicherry Institute of Medical Sciences, Pondicherry, India.

Background: Although the classic Reed-Sternberg (RS) cell is considered a diagnostic of Hodgkin's disease, RS-like cells have been noted in various benign and malignant conditions. The presence of these cells can be a diagnostic challenge.

Aims: Our aim was to see if cells morphologically resembling or identical to RS cells occur in conditions other than Hodgkin lymphoma (HL) and what proportion of cases show binucleate cells in various benign and malignant conditions. Read More

View Article and Full-Text PDF
February 2021

Genomics of diffuse large B cell lymphoma.

Authors:
Youngil Koh

Blood Res 2021 Apr;56(S1):S75-S79

Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.

Next generation sequencing (NGS) technology has revealed the heterogeneity of diffuse large B-cell lymphoma (DLBCL) from a mutation perspective. Accordingly, the conventional cell of origin-based classification of DLBCL has changed to a mutation-based classification. Mutation analysis delineates that B-cell receptor pathway activation, EZH2 mutation, and NOTCH mutations are distinctive drivers of DLBCL. Read More

View Article and Full-Text PDF

Immuno-oncology for B-cell lymphomas.

Authors:
Yoon Seok Choi

Blood Res 2021 Apr;56(S1):S70-S74

Department of Hematology-Oncology, Ajou University School of Medicine, Suwon, Korea.

The goal of cancer immunotherapy is to restore and optimize the immune response against malignant clones through several stages, from recognition of tumor antigens to establishment of long-lived memory cell populations. Boosting the intrinsic anti-tumor immune responses of the patients' own, several types of "active immunotherapies" have been tried in many types of malignancies, inspired by successful experiences of immune checkpoint inhibition even in Hodgkin lymphoma. However, in B-cell non-Hodgkin lymphomas, clinical usefulness of such "active immunotherapies" is relatively unsatisfactory considering the remarkable advances in "passive immunotherapy," including CD19-targeting chimeric antigen receptor T-cell therapy. Read More

View Article and Full-Text PDF

Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma.

Cancer Med 2021 May 1. Epub 2021 May 1.

Department of Hematology, University Hospital Vall d'Hebron, Barcelona, Spain.

Tisagenlecleucel (tisa-cel) is a second-generation autologous CD19-targeted chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). The approval was based on the results of phase II JULIET trial, with a best overall response rate (ORR) and complete response (CR) rate in infused patients of 52% and 40%, respectively. We report outcomes with tisa-cel in the standard-of-care (SOC) setting for R/R LBCL. Read More

View Article and Full-Text PDF

Ibrutinib improves the efficacy of anti-CD19-CAR T-cell therapy in patients with refractory non-Hodgkin lymphoma.

Cancer Sci 2021 May 1. Epub 2021 May 1.

Department of lymphoma, Tianjin Medical University Cancer Institute and Hospital. National Clinical Research Center of Cancer, Key laboratory of Cancer Prevention and Therapy. Tianjin's Clinical Research Center for Cancer, the Sino-US center for Lymphoma and Leukemia Research, Tianjin, China.

The efficacy and side effects of the second-time humanized CD19 chimeric antigen receptor (CD19-CAR) T-cell therapy after unsuccessful first-time anti-CD19-CAR T-cell therapy and subsequent ibrutinib salvage treatment were observed in patients with refractory B-cell lymphoma. In our study, three patients with refractory mantle cell lymphoma (MCL) and four patients with refractory follicular lymphoma (FL) reached stable disease (SD), partial remission (PR), or progression of disease (PD) after first-time humanized anti-CD19-CAR T-cell therapy. They received ibrutinib as a salvage treatment and kept a SD in the following 7-16 months, but their disease progressed again during ibrutinib salvage treatment. Read More

View Article and Full-Text PDF

Novel agents for the treatment of lymphomas during pregnancy: A comprehensive literature review.

Blood Rev 2021 Apr 16:100831. Epub 2021 Apr 16.

Division of Hematology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

Lymphoproliferative diseases occurring during pregnancy present unique diagnostic and therapeutic challenges aiming to achieve maternal cure without impairing fetal health, growth, and survival. These goals are further complicated by the fast-paced emergence of novel therapies and their introduction as standard of care, even in newly diagnosed patients. Due to the rarity of hematological malignancies in pregnancy and the exclusion of pregnancy in almost all clinical trials, available data on the fetal effects of novel drugs are limited to animal models and case reports. Read More

View Article and Full-Text PDF

Berberine exerts anti-tumor activity in diffuse large B-cell lymphoma by modulating c-myc/CD47 axis.

Biochem Pharmacol 2021 Apr 27:114576. Epub 2021 Apr 27.

Department of Hematology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, 250021, China; Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, 250021, China; School of Medicine, Shandong University, Jinan, Shandong, 250012, China; Shandong Provincial Engineering Research Center of Lymphoma, Jinan, Shandong, 250021, China; Branch of National Clinical Research Center for Hematologic Diseases, Jinan, Shandong, 250021, China; National Clinical Research Center for Hematologic Diseases, the First Affiliated Hospital of Soochow University, Suzhou 251006, China. Electronic address:

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma (NHL) with high clinical heterogeneity and poor prognosis. Immune escape mediated by CD47 overexpression contributes to the limited efficacy of rituximab, an anti-CD20 antibody, which indicates a target to improve the efficacy of DLBCL treatment. Here, we validated berberine, a natural compound, as a suppressor of CD47 and revealed the involved mechanism and biological function in DLBCL. Read More

View Article and Full-Text PDF

Economic and clinical outcomes of pegfilgrastim via prefilled syringe vs on-body injector: a real-world data analysis.

J Manag Care Spec Pharm 2021 Apr 30:1-9. Epub 2021 Apr 30.

Sandoz, Inc, Princeton, NJ.

Pegfilgrastim is available as a prefilled syringe (PFS) and an on-body injector (OBI). Whether the administration method of pegfilgrastim affects the effectiveness and health care resources has not been evaluated in the setting of routine care. To compare real-world clinical and economic outcomes between PFS and OBI methods of administration. Read More

View Article and Full-Text PDF

Quality of life and fear of cancer recurrence in patients and survivors of non-Hodgkin lymphoma.

Psychol Health Med 2021 Apr 30:1-12. Epub 2021 Apr 30.

School of Psychology, University of New England, Armidale, Australia.

Non-Hodgkin lymphoma (NHL) is a common haematological cancer that is comprised of approximately 30 subtypes, of which Waldenström Macroglobulinemia (WM) is a rare incurable form. It is typically managed using a watch-and-wait strategy that can contribute to illness uncertainty which may result in fear of cancer recurrence (FCR) and poor health-related quality of life (QOL). However, few studies have examined the correlates of FCR and QOL in NHL patients, including WM patients. Read More

View Article and Full-Text PDF

The evolving role of allogeneic haematopoietic cell transplantation in the era of chimaeric antigen receptor T-cell therapy.

Br J Haematol 2021 Apr 29. Epub 2021 Apr 29.

EBMT ALWP Office Hôpital Saint-Antoine, Paris, France.

Chimaeric antigen receptor T-cell (CAR T) therapy has revolutionized the management of many haematological malignancies. It is associated with impressive disease responses in relapsed or refractory high-grade B-cell non-Hodgkin lymphoma (B-NHL) and acute lymphoblastic leukaemia (B-ALL) with durable remissions in a subset of patients. Historically, haematopoietic cell transplantation (HCT) has been the standard consolidation strategy for many of these patients who are now being treated with CAR T. Read More

View Article and Full-Text PDF

FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials.

Eur J Nucl Med Mol Imaging 2021 Apr 29. Epub 2021 Apr 29.

Department of Nuclear Medicine, University Hospital Regensburg, Regensburg, Germany.

Purpose: Fluorine-18 fluorodeoxyglucose positron emission tomography combined with computed tomography (FDG PET/CT) is the standard for staging aggressive non-Hodgkin lymphoma (NHL). Limited data from prospective studies is available to determine whether initial staging by FDG PET/CT provides treatment-relevant information of bone marrow (BM) involvement (BMI) and thus could spare BM biopsy (BMB).

Methods: Patients from PETAL (NCT00554164) and OPTIMAL>60 (NCT01478542) with aggressive B-cell NHL initially staged by FDG PET/CT and BMB were included in this pooled analysis. Read More

View Article and Full-Text PDF

Late Effects after Chimeric Antigen Receptor T cell Therapy for Lymphoid Malignancies.

Transplant Cell Ther 2021 Mar 21;27(3):222-229. Epub 2020 Dec 21.

Taussig Cancer Center, Cleveland Clinic, Cleveland, OH.

Chimeric Antigen Receptor T-cell [CAR T] therapy has changed the treatment landscape of relapsed/refractory lymphoid malignancies. With an expanding pool of post CAR T-cell therapy survivors, prevention and management of late toxicities is emerging as an important component of survivorship care. This review summarizes the current state of evidence on late toxicities after CAR T-cell therapy in lymphoid malignancies. Read More

View Article and Full-Text PDF

Severe type-B lactic acidosis in a patient with bilateral renal Burkitt's lymphoma.

Clin Nephrol Case Stud 2021 26;9:49-53. Epub 2021 Apr 26.

Department of Medicine, Nephrology Section, University of Miami Miller School of Medicine/Miami VAMC, and.

Introduction: Lactic acidosis (LA) can be categorized as type A, which occurs in the presence of tissue hypoxia, or type B, occurring in the absence of tissue hypoxia. Hematologic malignancies are an uncommon cause of type B LA.

Case Presentation: A 63-year-old man, HIV-negative, with a history of diabetes mellitus, hypothyroidism, and non-alcoholic fatty liver disease (NAFLD), presented to the ED complaining of acute-on-chronic lumbar pain, and was found to have high serum anion gap (AG) LA. Read More

View Article and Full-Text PDF

Solid organ transplantation and survival among individuals with a history of cancer.

Cancer Epidemiol Biomarkers Prev 2021 Apr 29. Epub 2021 Apr 29.

Division of Cancer Epidemiology and Genetics, National Cancer Institute.

Background: The success of immunotherapy highlights a possible role for immunity in controlling cancer during remission for cancer patients in the general population. A prior cancer diagnosis is common among solid organ transplant candidates, and immunosuppressive medications administered to transplant recipients may increase recurrence risk.

Methods: Using linked data from the United States solid organ transplant registry and 13 cancer registries, we compared overall and cancer-specific survival among cancer patients who did vs. Read More

View Article and Full-Text PDF

Combined immune checkpoint blockade and radiotherapy induces durable remission in relapsed natural killer/T-cell lymphoma: a case report and review of the literature.

J Med Case Rep 2021 Apr 30;15(1):221. Epub 2021 Apr 30.

Division of Hematologic Malignancies and Stem Cell Transplantation, Harold. C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.

Background: Extranodal natural killer/T-cell lymphoma is a rare, aggressive non-Hodgkin lymphoma that is treated upfront mostly with L-asparaginase containing regimens. Relapsed extranodal natural killer/T-cell lymphoma is associated with a poor prognosis, and there is no established standard of care.

Case Presentation: We report the case of a 72 year-old white male with a distant extranasal relapse of extranodal natural killer/T-cell lymphoma that has been managed successfully with a combination of radiation and immune checkpoint blockade with pembrolizumab. Read More

View Article and Full-Text PDF

Clinical Perspectives of Theranostics.

Molecules 2021 Apr 13;26(8). Epub 2021 Apr 13.

Department of Radiology, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan.

Theranostics is a precision medicine which integrates diagnostic nuclear medicine and radionuclide therapy for various cancers throughout body using suitable tracers and treatment that target specific biological pathways or receptors. This review covers traditional theranostics for thyroid cancer and pheochromocytoma with radioiodine compounds. In addition, recent theranostics of radioimmunotherapy for non-Hodgkin lymphoma, and treatment of bone metastasis using bone seeking radiopharmaceuticals are described. Read More

View Article and Full-Text PDF